COVID-19 boosters offered to anyone ages 18 and older

Translate to Spanish or other 102 languages!

Image for illustration purposes.

Mega Doctor News

- Advertisement -

RIO GRANDE VALLEY, Texas – UT Health RGV is now offering COVID-19 boosters (Pfizer-BioNTech and Moderna) to anyone ages 18 and older.

All fully vaccinated people aged 18+ can get a booster at least 6 months after their second dose of Pfizer or Moderna or at least 2 months after initial dose of Johnson & Johnson.

Community members aged 5+ can get vaccinated at the following locations:

- Advertisement -

EDINBURG

Tuesday, Nov. 30, 1-6 p.m.

HARLINGEN

Wednesday, Dec. 1, 1-6 p.m.

- Advertisement -

MISSION

Wednesday, Dec. 1, 1-6 p.m.

  • V Express Care by UT Health RGV (at H-E-B plus!), located at 2409 East Expressway 83. (By appointment only – call for available dates and times at 956-296-2935.

FOR PARENTS AND GUARDIANS OF CHILDREN AGED 5-11

  • You willreceive a call from 1-833-888-2268 (1-833-UTVACN8 ) upon scheduling your child’s appointment. Please save this phone number 
  • This lower-dose Pfizer vaccine is the only COVID-19 vaccine to be authorized and recommended for use in children aged 5-11 years and should be administered as a two-dose series, three weeks apart — just as it is for people aged 12 and up.
  • Appointments for patient’s second dose will be scheduled on-site. 
  • All children under age 18 must be accompanied by a parent or guardian.

To make an appointment, log onto uthealth.org/vaccine or call 1-833-UTRGVMD.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

What Persistent Fatigue Might Be Telling You

Mega Doctor News CLEVELAND CLINIC - We’ve all had those days where we’re...

AMA Unveils New Initiative to Boost Nutrition Education Nationwide

The American Medical Association (AMA) is launching a nutrition education initiative to equip physicians and medical students with practical, evidence-based knowledge and tools to help patients live healthier lives.

DHR Health to Host Headache Symposium to Address Gap in Neurological Care, March 28th

In the United States, headaches remain a common health concern, affecting approximately one in six Americans. Migraines, a type of headache, are the second leading cause of years lived with disability nationwide.

Study Finds GLP‑1 Therapy Reduces Heart and Kidney Risks for Type 1 Diabetes Patients

People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and end-stage kidney disease without any increase in safety concerns, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
- Advertisement -